Our mission is to solve important clinical problems by applying principles from chemistry and engineering. The major focus of the laboratory is the development of imaging technology and contrast agents to see cancer at its smallest possible manifestation. Current medical technology only allows us to see a tumor once it is about the size of a spinning dime, the volume of which contains about 1 billion cancer cells. However, we believe Seeing is Curing-if we can see cancer at an earlier stage, we have a greater chance of curing it.
Our laboratory is addressing the cancer detection problem in three ways:
- First, we are developing novel imaging technology to improve cancer detection where it is needed most. We have developed the Fluorescence-Assisted Resection and Exploration (FLARETM) imaging system, and have its next generation technologies in clinical trials.
- Second, we are developing low molecular weight ligands, such as peptides and small molecules, which are able to "home" to cancer wherever it is located in the body.
- Finally, we are developing robust chemical methods for contrast agent generation using low molecular weight ligands.
By combining chemistry and engineering, we believe that cancer cells can be detected earlier and at a much smaller size, thus giving the patient the benefit of an earlier and more clear-cut diagnosis. With these advances, we someday hope to improve the probability of a cure.
More information is available on the
Frangioni Lab Website.